Long acting GLP-1 receptor agonist (injectable)
Liraglutide flexible dose injection once daily
LIRA_SC_FLEX_0p6-1p2-1p8_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.34 (-2.04 to 0.12) | 0.60 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.31 (0.04 to 1.65) | 0.85 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -5.66 (-9.24 to -2.10) | 0.86 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.81 (0.04 to 17.68) | 0.62 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.29 (0.32 to 4.24) | 0.58 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.30 (0.05 to 26.89) | 0.53 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 2.31 (0.52 to 10.79) | 0.20 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 2.38 (0.65 to 8.02) | 0.28 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 3.02 (0.71 to 12.46) | 0.45 |
| Children and adolescents with type 2 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.44 (0.40 to 5.05) | 0.44 |
Trials
- S0034272019 · 148 randomized · 52.14 weeks
- LIRA-PRIMEEfficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting2016 · 1,991 randomized · 104 weeks
- Ellipse™Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes2012 · 135 randomized · 52 weeks
- S0031082012 · 24 weeks